



<b>HUMANARZNEIMITTEL - EMA</b>	<b>2</b>
<i>Allgemeines – General</i>	2
<i>Pharmakovigilanz – PRAC</i>	2
<i>Zulassung – Regulatory Affairs</i>	3
<i>Orphan Drugs und neuartige Therapierichtungen (ATMP)</i>	4
<i>Qualität – Quality</i>	4
<i>(Prä-) Klinische Forschung – Research and Development</i>	5
<i>Kinderarzneimittel – Paediatrics</i>	5
<i>Pflanzliche Arzneimittel – Herbal medicines</i>	5
<i>Events and Video recording</i>	5
<b>EUROPEAN COMMISSION</b>	<b>6</b>
<b>EDQM</b>	<b>7</b>
<b>MEDIZINPRODUKTE</b>	<b>8</b>
<b>CMDH</b>	<b>9</b>
<b>HUMANARZNEIMITTEL - DEUTSCHLAND</b>	<b>10</b>
<b>HUMANARZNEIMITTEL - ÖSTERREICH</b>	<b>12</b>
<b>HUMANARZNEIMITTEL - SCHWEIZ</b>	<b>13</b>
 <b>FRAGEN AN DAS NETZWERK</b>	<b>14</b>
<b>VERANSTALTUNGEN / EVENTS – BEHÖRDEN UND ANDERE VERANSTALTER</b>	<b>15</b>
DEUTSCHLAND	15
ÖSTERREICH	15
SCHWEIZ	15
EUROPA	16
<u><a href="#">Urheberrechtshinweis:</a></u>	

Der MEGRA Newsletter und die darin enthaltenen Beiträge sind urheberrechtlich geschützt. Ohne die ausdrückliche Genehmigung der Urheber oder der Inhaber der Nutzungsrechte darf weder der MEGRA Newsletter noch Teile davon verbreitet, bearbeitet, öffentlich zugänglich, vorgetragen, in einem Abrufsystem gespeichert oder in ein solches eingeführt oder in einer beliebigen anderen Form (elektronisch, mechanisch, per Hyperlink, per Fotokopie, per Aufzeichnung oder auf anderem Wege) oder zu einem beliebigen anderen Zweck vervielfältigt oder übermittelt werden. Downloads und Kopien des Newsletters sind nur Mitgliedern der *Mittel Europäischen Gesellschaft für Regulatory Affairs e.V. (MEGRA)* und für den privaten, nicht kommerziellen Gebrauch gestattet. Durch das Herunterladen oder Kopieren von Inhalten werden keine Rechte bezüglich der Inhalte übertragen.

## Allgemeines – General

### **Podcast: Inside EMA (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/news-events/podcast-inside-ema>

### **SME Regulation and reports (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/support-smes/sme-regulation-reports>

### **Artificial intelligence (updated)**

**Published on:** 04 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/artificial-intelligence>

## Pharmakovigilanz – PRAC

### **Guideline on good pharmacovigilance practices (GVP): Module VII – Periodic safety update report - Explanatory note (updated)**

**Published on:** 22 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report-explanatory-note\\_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report-explanatory-note_en.pdf)

### **Questions and answers on periodic safety update report single-assessment (PSUSA): Guidance document for assessors (updated)**

**Published on:** 22 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-periodic-safety-update-report-single-assessment-psusa-guidance-document-assessors\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/questions-answers-periodic-safety-update-report-single-assessment-psusa-guidance-document-assessors_en.pdf)

### **List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-eurd-frequency-submission-periodic-safety-update-reports-psurs\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/list-european-union-reference-dates-eurd-frequency-submission-periodic-safety-update-reports-psurs_en.xlsx)

### **List of medicines under additional monitoring (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring>

## Humanarzneimittel - EMA

**List of centrally authorised products with safety-related changes to the product information (updated)**

**Published on:** 29 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorized-products-safety-related-changes-product-information\\_en.xlsx](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/list-centrally-authorized-products-safety-related-changes-product-information_en.xlsx)

**New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC (updated)**

**Published on:** 01 - June - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac\\_en.pdf](https://www.ema.europa.eu/en/documents/prac-recommendation/new-product-information-wording-extracts-prac-recommendations-signals-adopted-12-15-january-2026-prac_en.pdf)

**Referral: Tecovirimat SIGA**

**Published on:** 02 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/medicines/human/referrals/tecovirimat-siga>

### Zulassung – Regulatory Affairs

**Medicinal products for human use: monthly figures - April 2026**

**Published on:** 26 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2026\\_en.pdf](https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-april-2026_en.pdf)

**Timetable: Annual reassessment (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/timetable-annual-reassessment\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/timetable-annual-reassessment_en.xlsx)

**Timetable: Annual renewal application of conditional marketing authorisation (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/timetable-annual-renewal-application-conditional-marketing-authorisation\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/timetable-annual-renewal-application-conditional-marketing-authorisation_en.xlsx)

**Timetable: Marketing authorisation renewal application (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/timetable-marketing-authorisation-renewal-application\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/timetable-marketing-authorisation-renewal-application_en.xlsx)

## Humanarzneimittel - EMA

### **Real-world evidence (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence>

### **EMA's API general terms and conditions of use - Terms of use (updated)**

**Published on:** 03 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/es/media/49662>

### **Scientific guideline: Development of a reflection paper on the use of external controls for evidence generation in regulatory decision-making (updated)**

**Published on:** 03 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/es/development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making-scientific-guideline>

### **Medicines for human use under evaluation (updated)**

**Published on:** 03 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/es/medicines/medicines-human-use-under-evaluation>

## Orphan Drugs und neuartige Therapierichtungen (ATMP)

### **Timetable: Annual reassessment - ATMP (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/timetable-annual-reassessment-atmp\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/timetable-annual-reassessment-atmp_en.xlsx)

### **Timetable: Annual renewal application of conditional marketing authorisation - ATMP (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/timetable-annual-renewal-application-conditional-marketing-authorisation-atmp\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/timetable-annual-renewal-application-conditional-marketing-authorisation-atmp_en.xlsx)

### **Timetable: Marketing authorisation renewal application - ATMP (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/other/timetable-marketing-authorisation-renewal-application-atmp\\_en.xlsx](https://www.ema.europa.eu/en/documents/other/timetable-marketing-authorisation-renewal-application-atmp_en.xlsx)

## Qualität – Quality

**No news published**

# Humanarzneimittel - EMA

## (Prä-) Klinische Forschung – Research and Development

### **Accelerating Clinical Trials in the EU (ACT EU) (updated)**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/accelerating-clinical-trials-eu-act-eu>

### **Clinical pharmacology and pharmacokinetics: questions and answers (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics-guidelines/clinical-pharmacology-pharmacokinetics-questions-answers>

### **Product Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 3 (updated)**

**Published on:** 28 - May - 2026

**For more information, please refer to:**

[https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-3\\_en.pdf](https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/product-management-services-pms-implementation-international-organization-standardization-iso-standards-identification-medicinal-products-idmp-europe-chapter-3_en.pdf)

## Kinderarzneimittel – Paediatrics

### **Enpr-EMA priority activities (updated)**

**Published on:** 29 - May - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/partners-networks/networks/european-network-paediatric-research-european-medicines-agency-enpr-ema/enpr-ema-priority-activities>

## Pflanzliche Arzneimittel – Herbal medicines

**No news published**

## Events and Video recording

**No news published**

**Commission publishes analysis underpinning the Biotech Act proposals**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

<https://ec.europa.eu/newsroom/sante/newsletter-archives/75672>

**Health Technology Assessment: New Opportunity to Apply for Joint Scientific Consultations**

**Published on:** 01 - June - 2026

**For more information, please refer to:**

<https://ec.europa.eu/newsroom/sante/newsletter-archives/75918>

***The European Pharmacopoeia Commission intensifies its efforts on quality control guidance for preparations for inhalation and nasal administration***

***Published on: 28 - May - 2026***

***For more information, please refer to:***

***<https://www.edqm.eu/en/-/the-european-pharmacopoeia-commission-intensifies-its-efforts-on-quality-control-guidance-for-preparations-for-inhalation-and-nasal-administration>***

***EDQM reference standards monthly newsletter – May 2026***

***Published on: 01 - June - 2026***

***For more information, please refer to:***

***<https://www.edqm.eu/en/-/edqm-reference-standards-monthly-newsletter-may-2026>***

***OMCL Network Symposium reaffirms commitment to combating falsified and other illegal medicines***

***Published on: 05 - June - 2026***

***For more information, please refer to:***

***<https://www.edqm.eu/en/-/omcl-network-symposium-reaffirms-commitment-to-combating-falsified-and-other-illegal-medicines>***

## Medizinprodukte

***Scientific advice for high-risk medical devices (updated)***

***Published on:*** 29 - May - 2026

***For more information, please refer to:***

<https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices/high-risk-medical-devices/scientific-advice-high-risk-medical-devices>

***Expert panel support for breakthrough medical devices: pilot programme (updated)***

***Published on:*** 04 - June - 2026

***For more information, please refer to:***

<https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices/expert-panel-support-breakthrough-medical-devices-pilot-programme>

***The first four modules of EUDAMED became mandatory since 28 May 2026***

***Published on:*** 01 - June - 2026

***For more information, please refer to:***

[https://health.ec.europa.eu/medical-devices-eudamed/overview\\_en](https://health.ec.europa.eu/medical-devices-eudamed/overview_en)

**NEW - Report from the meeting held on 19-20 May 2026**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/press-releases.html>

**UPDATE - Non Clinical / Clinical AR for Generics - MRP & DCP**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/templates/assessment-reports/dcp-ar/comments.html>

**NEW - 21-22 April CMDh Minutes**

**Published on:** 27 - May - 2026

**For more information, please refer to:**

<https://www.hma.eu/human-medicines/cmdh/agendas-and-minutes.html>

# Humanarzneimittel - Deutschland

## **Sachstandstabelle**

**Veröffentlicht am:** 22 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Zulassung/Zulassungsrelevante-Themen/Expertengruppe-Off-Label/sachstandstabelle.html?nn=986770>

## **Liste der Mitglieder und Stellvertretungen des Sachverständigen-Ausschusses für Apothekenpflicht**

**Veröffentlicht am:** 26 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Gremien/Apothekenpflicht/liste-mitglieder.html?nn=986770>

## **Europäische Datenbank für Medizinprodukte: EUDAMED**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Medizinprodukte/Ueberblick/Europa-und-EUDAMED/EUDAMED/artikel.html?nn=986770>

## **Anleitung für Anzeigepflichtige Adressanzeigen**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Medizinprodukte/DMIDS-anleitung-anzeigepflichtige-adressen.html?nn=986770>

## **Erst- und Änderungsanzeige MP und IVD**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Medizinprodukte/DMIDS-anleitung-anzeigepflichtige-mp-ivd.html?nn=986770>

## **Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 26.03.2026 betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Epinephrin/Adrenalin (außer nasale Anwendung)**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

[https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports\\_PSURs/PSUR-Single-Assessment/Anlagen/a-f/Epinephrin-Adrenalin-CMDh-Beschluss.html?nn=986770](https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports_PSURs/PSUR-Single-Assessment/Anlagen/a-f/Epinephrin-Adrenalin-CMDh-Beschluss.html?nn=986770)

## **Muster: Dokumentation „Nicht Supervisory Authority Inspektion“**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/muster-pharmakovigilanz-non-sa-inspektionen.html?nn=986770>

# Humanarzneimittel - Deutschland

**Muster: Dokumentation „Supervisory Authority Inspektion“**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/muster-pharmakovigilanz-sa-inspektionen.html?nn=986770>

**Ein Jahr European Vaccines Hub: Paul-Ehrlich-Institut trägt dazu bei, die europäische Pandemievorsorge nachhaltig zu stärken**

**Veröffentlicht am:** 29 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.pei.de/DE/newsroom/hp-meldungen/2026/260529-1-jahr-evh.html?nn=170852>

**Offene ordnungsgemäß eingegangene Anträge auf Zulassung und Registrierung für Arzneimittel im Zuständigkeitsbereich des BfArM**

**Veröffentlicht am:** 01 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Aktuelles/Statistiken/Arzneimittelzulassung/offene-Zulassungsantraege/artikel.html?nn=986770>

**Aktuell laufende und bestätigte Arzneimittel-Härtefallprogramme**

**Veröffentlicht am:** 02 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/compUse-tabelle.html?nn=986770>

**Informationen zu Einreichung und Genehmigung von Schulungsmaterial**

**Veröffentlicht am:** 02 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Schulungsmaterial/Zusatzeinformationen/artikel.html?nn=986770>

**Maßnahmen des BfArM und ergänzende Informationen zu Lieferengpässen**

**Veröffentlicht am:** 05 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/artikel.html?nn=986770>

## Humanarzneimittel - Österreich

### **FAQ Bevorratung national**

**Veröffentlicht am:** 28 - Mai - 2026

**Weitere Informationen finden Sie unter:**

<https://www.basq.gv.at/fuer-unternehmen/online-service/faq-online-service/faq-bevorratung-national>

### **PSUR-outcome: Metronidazol/Neomycin/Nystatin**

**Veröffentlicht am:** 05 - Juni - 2026

**Weitere Informationen finden Sie unter:**

[Link zur Website der EMA](#)

## Humanarzneimittel - Schweiz

### **Safety Update – Aktualisierungen der Fachinformation**

**Veröffentlicht am:** 01 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/risk-management-rmps/safetyupdates.html>

### **swissdamed Webinar 28 May 2026: How to register and manage medical device data in swissdamed**

*Presentation and Video recordings available*

**Published on:** 01 - Juni - 2026

**For more information, please refer to:**

<https://www.swissmedic.ch/swissmedic/de/home/services/veranstaltungen/swissdamed-webinar.html>

### **Swissmedic Journal**

**Veröffentlicht am:** 04 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/publikationen/swissmedic-journal.html>

### **Aktualisierte Vorgabedokumente**

**Veröffentlicht am:** 05 - Juni - 2026

**Weitere Informationen finden Sie unter:**

[https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated\\_documents.html](https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents.html)



## Fragen an das Netzwerk

**Falls Sie eine Frage haben, die Sie gerne in unserem Netzwerk diskutieren würden, senden Sie uns einfach eine E-Mail an [info-as@megra.org](mailto:info-as@megra.org) zur anonymen Publikation im nächsten Newsletter.\***

\*Bei der Beantwortung der Fragen handelt es sich um eine Zusammenfassung von persönlichen Meinungen und Erfahrungswerten der MEGRA Mitglieder mit keinem Anspruch auf Rechtssicherheit. Wir empfehlen zur Absicherung die Konsultation entsprechender zugrunde liegender Regularien.

# Veranstaltungen / Events – Behörden und andere Veranstalter

## Deutschland

### **Mit BfArM und PEI im Dialog: CTR und mehr**

**Ort:** online

**Termin:** 15 - Juni - 2026

**Weitere Informationen finden Sie unter:**

<https://www.pei.de/SharedDocs/veranstaltungen-events/DE/2026/2026-06-15-ctr-dialog-bfarm-pei.html?nn=170994>

### **Internationales Paul-Ehrlich-Seminar (IPES)**

**Ort:** Stadthalle Langen (bei Frankfurt)

**Termin:** 02 bis 05 - September - 2026

**Weitere Informationen finden Sie unter:**

<https://www.pei.de/DE/newsroom/hp-meldungen/2026/260216-ipes-2026-registrierung-gestartet.html?nn=170852>

### **SNOMED-CT-Basiserschulung: ECL**

**Ort:** online

**Termin:** 17 - September - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Aktuelles/Veranstaltungen/Termine/2026-09-17-snomed-eclschulung.html?nn=986770>

### **genomDE Symposium**

**Ort:** Bundeskunsthalle, Bonn

**Termin:** 28 bis 29 - September - 2026

**Weitere Informationen finden Sie unter:**

<https://www.bfarm.de/DE/Aktuelles/Veranstaltungen/Termine/2026-09-28-genom.html?nn=986770>

## Österreich

**Keine Veranstaltungen veröffentlicht**

## Schweiz

### **Save the Date: Regulatory & Beyond 2026**

**Ort:** Kursaal Bern

**Termin:** 16 - November - 2026

**Weitere Informationen finden Sie unter:**

<https://www.swissmedic.ch/swissmedic/de/home/services/veranstaltungen/regulatory-beyond-2026.html>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### Europa

#### **Q&A clinic on Substance, Organisation, Referentials Management Services - 2026**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 10 - June - 2026, 08 - July - 2026, 09 - September - 2026, 07 - October - 2026, 11 - November - 2026, 09 - December - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/qa-clinic-substance-organisation-referentials-management-services-june-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-substance-organisation-referentials-management-services-july-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-substance-organisation-referentials-management-services-september-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-substance-organisation-referentials-management-services-october-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-substance-organisation-referentials-management-services-november-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-substance-organisation-referentials-management-services-december-2026>

#### **PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) - 2026**

**Where:** online

**Date:** 11 - June – 2026, 25 - June - 2026, 09 - July - 2026, 23 - July - 2026, 10 - September - 2026, 24 - September - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/pms-qa-clinic-product-user-interface-pui-application-programming-interface-api-june-2026>

<https://www.ema.europa.eu/en/events/pms-qa-clinic-product-user-interface-pui-application-programming-interface-api-june-2026-0>

<https://www.ema.europa.eu/en/events/pms-qa-clinic-product-user-interface-pui-application-programming-interface-api-july-2026>

<https://www.ema.europa.eu/en/events/pms-qa-clinic-product-user-interface-pui-application-programming-interface-api-july-2026-0>

<https://www.ema.europa.eu/en/events/pms-qa-clinic-product-user-interface-pui-application-programming-interface-api-september-2026>

<https://www.ema.europa.eu/en/events/pms-qa-clinic-product-user-interface-pui-application-programming-interface-api-september-2026-0>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPPD) service - 2026**

**Where:** online

**Date:** 11 - June - 2026, 09 - July - 2026, 10 - September - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/qa-clinic-extended-eudravigilance-medicinal-product-dictionary-xevmpd-service-june-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-extended-eudravigilance-medicinal-product-dictionary-xevmpd-service-july-2026>

<https://www.ema.europa.eu/en/events/qa-clinic-extended-eudravigilance-medicinal-product-dictionary-xevmpd-service-september-2026>

### **Updates to industry contact management for authorisation products (IRIS)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 11 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/es/node/281811>

### **European platform for regulatory science research meeting: June 2026**

**Where:** online

**Date:** 16 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/european-platform-regulatory-science-research-meeting-june-2026>

### **Clinical Trials Information System (CTIS): Information day**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 17 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-information-day-2>

### **Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - 2026**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 22 to 26 - June - 2026, 14 to 18 - September - 2026, 12 to 16 - October - 2026, 09 to 13 - November - 2026, 07 to 11 - December - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-inthe-eu-hands-training-course-using-eudravigilance-system-4>

<https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-55>

<https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-56>

<https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-57>

<https://www.ema.europa.eu/en/events/mandatory-use-iso-ich-e2br3-individual-case-safety-reporting-eu-hands-training-course-using-eudravigilance-system-58>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Quarterly System Demo - 2026**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 25 - June - 2026, 17 - September - 2026, 10 - December - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/quarterly-system-demo-q2-2026>

<https://www.ema.europa.eu/en/events/quarterly-system-demo-q3-2026>

<https://www.ema.europa.eu/en/events/quarterly-system-demo-q4-2026>

### **Webinar: Everything you ever wanted to know about the certification of suitability procedure**

**Where:** Paris, France

**Date:** 26 - June - 2026

**For more information, please refer to:**

<https://www.edqm.eu/en/-/webinar-everything-you-ever-wanted-to-know-about-the-certification-of-suitability-procedure-register-now->

### **EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia**

**Where:** online

**Date:** 30 - June - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/ema-workshop-challenges-drug-development-regulation-clinical-practice-immune-thrombocytopenia>

### **Good manufacturing practice: Multistakeholder workshop on expert contributions to artificial intelligence guidance development (Annex 22)**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 30 - June to 01 - July - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/good-manufacturing-practice-multistakeholder-workshop-expert-contributions-artificial-intelligence-guidance-development-annex-22>

### **EMA risk management information day**

**Where:** European Medicines Agency, Amsterdam, the Netherlands

**Date:** 08 - September - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/ema-risk-management-information-day>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **Joint EDQM-USP International Symposium on Pharmaceutical Reference Standards**

**Where:** EDQM building, Strasbourg, France & Online

**Date:** 23 to 24 - September - 2026

**For more information, please refer to:**

[https://www.edqm.eu/en/irss-event?p\\_l\\_back\\_url=%2Fen%2Fgroup%2Fedqm%2F%7E%2Fcontrol\\_panel%2Fmanage%3Fp\\_p\\_id%3Dcom\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet%26p\\_p\\_lifecycle%3D0%26p\\_p\\_state%3Dmaximized%26p\\_p\\_mode%3Dview%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_tabs1%3Dpages%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_privateLayout%3Dfalse%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_displayStyle%3Dmiller-columns%26p\\_r\\_p\\_selPlid%3D2070%26p\\_r\\_p\\_layoutSetBranchId%3D0%26p\\_p\\_auth%3DLI4b0kqf](https://www.edqm.eu/en/irss-event?p_l_back_url=%2Fen%2Fgroup%2Fedqm%2F%7E%2Fcontrol_panel%2Fmanage%3Fp_p_id%3Dcom_liferay_layout_admin_web_portlet_GroupPagesPortlet%26p_p_lifecycle%3D0%26p_p_state%3Dmaximized%26p_p_mode%3Dview%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_tabs1%3Dpages%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_privateLayout%3Dfalse%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_displayStyle%3Dmiller-columns%26p_r_p_selPlid%3D2070%26p_r_p_layoutSetBranchId%3D0%26p_p_auth%3DLI4b0kqf)

### **CPhI Worldwide & CEP One-to-One Sessions**

**Where:** Fiera Milano, Milan, Italy

**Date:** 06 to 08 - October - 2026

**For more information, please refer to:**

[https://www.edqm.eu/en/cphi-milan?p\\_l\\_back\\_url=%2Fen%2Fgroup%2Fedqm%2F%7E%2Fcontrol\\_panel%2Fmanage%3Fp\\_p\\_id%3Dcom\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet%26p\\_p\\_lifecycle%3D0%26p\\_p\\_state%3Dmaximized%26p\\_p\\_mode%3Dview%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_tabs1%3Dpages%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_privateLayout%3Dfalse%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_displayStyle%3Dmiller-columns%26p\\_r\\_p\\_selPlid%3D2070%26p\\_r\\_p\\_layoutSetBranchId%3D0%26p\\_p\\_auth%3Dun7FrSXJ](https://www.edqm.eu/en/cphi-milan?p_l_back_url=%2Fen%2Fgroup%2Fedqm%2F%7E%2Fcontrol_panel%2Fmanage%3Fp_p_id%3Dcom_liferay_layout_admin_web_portlet_GroupPagesPortlet%26p_p_lifecycle%3D0%26p_p_state%3Dmaximized%26p_p_mode%3Dview%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_tabs1%3Dpages%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_privateLayout%3Dfalse%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_displayStyle%3Dmiller-columns%26p_r_p_selPlid%3D2070%26p_r_p_layoutSetBranchId%3D0%26p_p_auth%3Dun7FrSXJ)

### **Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting in the EU: Hands-on training course using the EudraVigilance System - 2026**

**Where:** online and European Medicines Agency, Amsterdam, the Netherlands

**Date:** 06 to 08 - October - 2026, 24 to 26 - November - 2026

**For more information, please refer to:**

<https://www.ema.europa.eu/en/events/virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-october-2026>

<https://www.ema.europa.eu/en/events/virtual-live-hands-training-course-clinical-trials-sponsors-using-eudravigilance-system-november-2026>

### **SAVE THE DATE! EDQM Symposium: Microbiology on the Move**

**Where:** Strasbourg, France

**Date:** 13 to 15 - October - 2026

**For more information, please refer to:**

<https://www.edqm.eu/en/-/symposium-microbio>

## Veranstaltungen / Events – Behörden und andere Veranstalter

### **CPHI India & CEP One-to-One Sessions**

**Where:** IICC, Yashobhoomi, Dwarka, Delhi

**Date:** 23 to 25 - November - 2026

**For more information, please refer to:**

[https://www.edqm.eu/en/cphi-india-cep-one-to-one-sessions?p\\_l\\_back\\_url=%2Fen%2Fgroup%2Fedqm%2F~%2Fcontrol\\_panel%2Fmanage%3Fp\\_p\\_id%3Dcom\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet%26p\\_p\\_lifecycle%3D0%26p\\_p\\_state%3Dmaximized%26p\\_p\\_mode%3Dview%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_tabs1%3Dpages%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_privateLayout%3Dfalse%26com\\_liferay\\_layout\\_admin\\_web\\_portlet\\_GroupPagesPortlet\\_displayStyle%3Dmiller-columns%26p\\_r\\_p\\_selPlid%3D2070%26p\\_r\\_p\\_layoutSetBranchId%3D0%26p\\_p\\_auth%3DHQfjd1mP](https://www.edqm.eu/en/cphi-india-cep-one-to-one-sessions?p_l_back_url=%2Fen%2Fgroup%2Fedqm%2F~%2Fcontrol_panel%2Fmanage%3Fp_p_id%3Dcom_liferay_layout_admin_web_portlet_GroupPagesPortlet%26p_p_lifecycle%3D0%26p_p_state%3Dmaximized%26p_p_mode%3Dview%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_tabs1%3Dpages%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_privateLayout%3Dfalse%26com_liferay_layout_admin_web_portlet_GroupPagesPortlet_displayStyle%3Dmiller-columns%26p_r_p_selPlid%3D2070%26p_r_p_layoutSetBranchId%3D0%26p_p_auth%3DHQfjd1mP)